The tumor suppressor protein p16(INK4a)

Experimental Cell Research

Volumn 237, Issue 1, 1997, Pages 7-13

  Serrano, Manuel ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P16; RETINOBLASTOMA PROTEIN;

CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; GENE LOCUS; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0031586589     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1997.3824     Document Type: Article

References (85)

1. 1. Xiong, Y., Zhang, H., and Beach, D. (1993). Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7, 1572-1583.
2. 2. Serrano, M., Hannon, G. J., and Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
3. 3. Sherr, C. J. (1993). Mammalian G1 cyclins. Cell 73, 1059-1065.
4. 4. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
5. 5. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
6. INK4 in human cancer. Proc. Natl. Acad. Sci. USA 91, 11045-11049.
7. 7. Hirama, T., and Koeffler, H. P. (1995). Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86, 841-854.
8. 8. Palmero, I., and Peters, G. (1997). Perturbations of cell cycle regulators in human cancer. Cancer Surv. 27, 351-367.
9. 9. Foulkes, W. D., Flanders, T. Y., Pollock, P. M., and Hayward, N. K. (1997). The CDKN2A (p16) gene and human cancer. Mol. Med. 3, 5-20.
10. 10. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-690.
11. 11. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525-4530.
12. 12. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. (1995). Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531-4535.
13. 13. Scutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Scwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126-3130.
14. 14. Chaubert, P., Gayer, R., Zimmermann, A., Fontolliet, C., Stamm, B., Bosnian, F., and Shaw, P. (1997). Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 25, 1376-1381.
15. 15. Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37.
16. INK4 is a potential effector of cell cycle arrest mediated by TGF-β. Nature 371, 257-261.
17. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8, 2939-2952.
18. 18. Hirai, H., Roussel, M. F., Kato, J., Ashmun, R. A., and Sherr, C. J. (1995). Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15, 2672-2681.
19. ink4. Mol. Cell. Biol. 15, 2682-2688.
20. 20. Nairn, R. S., Kazianis, S., McEntire, B. B., Della Coletta, L., Walter, R. B., and Morizot, D. C. (1996). A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids. Proc. Natl. Acad. Sci. USA 93, 13042-13047.
21. 1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
22. 22. Sidransky, D. (1996). Two tracks but one race? Curr. Biol. 6, 523-525.
23. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867.
24. 24. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000.
25. ARF. Proc. Natl. Acad. Sci. USA 94, 669-673.
26. INK4d. Nature 389, 999-1002.
27. 27. Gorina, S., and Pavletich, N. P. (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001-1005.
28. 28. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503-506.
29. 29. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. (1995). Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510.
30. INK4 function. Nature Genet. 10, 114-116.
31. 31. Reymond, A., and Brent, R. (1995). P16 proteins from melanoma families are deficient in binding to Cdk4. Oncogene 11, 1173-1178.
32. 32. Wick, S. T., Dubay, M. M., Imanil, I., and Brizuela, L. (1995). Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product p16. Oncogene 11, 2013-2019.
33. INK4a tumor suppressor protein. Cancer Res. 55, 2503-2506.
34. INK4a and its interaction with CDK4. Biochem. Biophys. Res. Commun. 218, 254-259.
35. 35. Lilischkis, R., Sarcevic, B., Kennedy, C., Warlters, A., and Sutherland, R. L. (1996). Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int. J. Cancer 66, 249-254.
36. INK4a/CDKN2A in human glioma. Oncogene 14, 603-609.
37. INK4a: Structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Biochemistry 35, 9475-9487.
38. 38. Zhang, B., and Peng, Z. (1996). Defective folding of mutant p16(INK4) proteins encoded by tumor-derived alleles. J. Biol. Chem. 271, 28734-28737.
39. CDKN2/INK4A. Curr. Biol. 6, 84-91.
40. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
41. 41. Coleman, K. G., Wautlet, B. S., Morrisey, D., Mulheron, J., Sedman, S. A., Brinkley, P., Price, S., and Webster, K. R. (1997). Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J. Biol. Chem. 272, 18869-18874.
42. INK4a-binding interface in CDK4. Submitted for publication.
43. 43. Reynisdóttir, I., and Massagué, J. (1997). The subcellular locations of p15Ink4b and p27Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11, 492-503.
44. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382, 325-331.
45. INK4/MTS1 tumour suppressor gene product. EMBO J. 14, 503-511.
46. INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol. Cell. Biol. 17, 2458-2467.
47. 47. Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
48. 48. Hurford, R. K., Jr., Cobrinik, D., Lee, M.-H., and Dyson, N. (1997). pRb and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11, 1447-1463.
49. INK4. Science 267, 249-252.
50. ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA 92, 6289-6293.
51. INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505-509.
52. 52. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150-153.
53. 53. Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. (1994). CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321-6324.
54. 54. He, J., Olson, J. J., and James, C. D. (1995). Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4, is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55, 4833-4836.
55. 55. Maelandsmo, G. M., Berner, J.-M., Flörenes, V. A., Forus, A., Hovig, E., Fodstad, O., and Myklebost, O. (1995). Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas: Relationship to amplification and mRNA levels of CDK4 and CCND1. Br. J. Cancer 72, 393-398.
56. 56. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. (1994). Germline p16 mutations in familial melanoma. Nature Genet. 8, 15-21.
57. INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99.
58. 58. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. (1995). Complex structure and regulation of p16 (MTS1) locus. Cancer Res. 55, 2988-2994.
59. INK4b genes. Oncogene 11, 635-645.
60. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211.
61. INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 15, 495-503.
62. 62. Votja, P. J., and Barrett, J. C. (1995). Genetic analysis of cellular senescence. Biochim. Biophys. Acta 1242, 29-41.
63. 1 arrest in senescent human fibroblasts. Bioessays 17, 537-543.
64. 64. Atadja, P., Wong, H., Garkavtsev, I., Veillette, and Riabowol, K. (1995). Increased activity of p53 in senescing fibroblasts. Proc. Natl. Acad. Sci. USA 92, 8348-8352.
65. 65. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211, 90-98.
66. 66. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93, 13742-13747.
67. 67. Tahara, H., Sato, E., Noda, A., and Ide, T. (1995). Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 10, 835-840.
68. 68. Reznikoff, C. A., Yeager, T. R., Belair, C. D., Savelieva, E., Puthenveettil, J. A., and Stadler, W. M. (1996). Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56, 2886-2890.
69. 69. Loughran, O., Malliri, A., Owens, D., Gallimore, P. H., Stanley, M. A., Ozanne, B., Frame, M. C., and Parkinson, E. K. (1996). Association of CDKN2/p16INK4a with human head and neck keratinocyte replicative senescence: Relationship of dysfunction to immortality and neoplasia. Oncogene 13, 561-568.
70. 70. England, N. L., Cuthbert, A. P., Trott, D. A., Jezzard, S., Nobori, T., Carson, D. A., and Newbold, R. F. (1996). Identification of human tumour suppressor genes by monochromosome transfer: Rapid growth-arrest response mapped to 9p21 is mediated solely by the cyclin-D-dependent kinase inhibitor gene, CDKN2 (p16INK4a). Carcinogenesis 17, 1567-1575.
71. INK4a and counteracts its inhibitory activity towards CDK4. EMBO J. 15, 1607-1614.
72. INK4a. J. Virol. 71, 1956-1962.
73. 73. Downward, J. (1997). Routine role for Ras. Curr. Biol. 7, 258-260.
74. 74. Peeper, D. S., and Bernards, R. (1997). Communication between the extracellular environment, cytoplasmic signalling cascades and the nuclear cell-cycle machinery. FEBS Lett. 410, 11-16.
75. 75. Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., and Ewen, M. E. (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177-181.
76. KIP1. Mol. Cell. Biol. 17, 3850-3857.
77. 77. Mittnacht, S., Paterson, H., Olson, M. F., and Marshall, C. J. (1997). Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr. Biol. 7, 219-221.
78. INK4a. Cell 88, 593-602.
79. 79. Weinberg, R. A. (1997). The cat and mouse games that genes, viruses, and cells play. Cell 88, 573-575.
80. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med. 3, 313-319.
81. Ink4. Cancer Res. 54, 5816-5820.
82. 82. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. (1994). Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54, 6078-6082.
83. 83. Xiong, Y., Kuppuswamy, D., Li, Y., Livanos, E. M., Hixon, M., White, A., Beach, D., and Tlsty, T. D. (1996). Alteration of cell cycle kinase complexes in human papillomavirus E6-and E7-expressing fibroblasts precedes neoplastic transformation. J. Virol. 70, 999-1008.
84. 84. Khleif, S. N., DeGregori, J., Yee, C. L., Otterson, G. A., Kaye, F. J., Nevins, J. R., and Howley, P. M. (1996). Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. USA 93, 4350-4354.
85. 85. Soucek, T., Pusch, O., Hengstschlager-Ottnad, E., Wawra, E., Bernaschek, G., and Hengstschlager, M. (1995). Expression of the cyclin-dependent kinase inhibitor p16 during the ongoing cell cycle. FEBS Lett. 373, 164-169.